scholarly journals Amplifying antitumor T cell immunity with versatile drug delivery systems for personalized cancer immunotherapy

2021 ◽  
pp. 100116
Author(s):  
Ping Xiao ◽  
Yaping Li ◽  
Dangge Wang
2020 ◽  
Vol 65 (17) ◽  
pp. 1489-1504
Author(s):  
Chen Yang ◽  
Nicholas Thomas Blum ◽  
Jing Lin ◽  
Junle Qu ◽  
Peng Huang

2019 ◽  
Vol 85 ◽  
pp. 1-26 ◽  
Author(s):  
Pingsheng Huang ◽  
Xiaoli Wang ◽  
Xiaoyu Liang ◽  
Jing Yang ◽  
Chuangnian Zhang ◽  
...  

2010 ◽  
Vol 16 (19) ◽  
pp. 4695-4701 ◽  
Author(s):  
Luca Gattinoni ◽  
Yun Ji ◽  
Nicholas P. Restifo

Author(s):  
Rongwei Cui ◽  
Qiang Wu ◽  
Jing Wang ◽  
Xiaoming Zheng ◽  
Rongying Ou ◽  
...  

Immunotherapy has emerged as a promising strategy for cancer treatment, in which durable immune responses were generated in patients with malignant tumors. In the past decade, biomaterials have played vital roles as smart drug delivery systems for cancer immunotherapy to achieve both enhanced therapeutic benefits and reduced side effects. Hydrogels as one of the most biocompatible and versatile biomaterials have been widely applied in localized drug delivery systems due to their unique properties, such as loadable, implantable, injectable, degradable and stimulus responsible. Herein, we have briefly summarized the recent advances on hydrogel-by-design delivery systems including the design of hydrogels and their applications for delivering of immunomodulatory molecules (e.g., cytokine, adjuvant, checkpoint inhibitor, antigen), immune cells and environmental regulatory substances in cancer immunotherapy. We have also discussed the challenges and future perspectives of hydrogels in the development of cancer immunotherapy for precision medicine at the end.


2021 ◽  
Vol 6 (59) ◽  
pp. eabh2383
Author(s):  
Xi Wang ◽  
Bo Li ◽  
Yu Jeong Kim ◽  
Yu-Chen Wang ◽  
Zhe Li ◽  
...  

Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain, where it breaks down neurotransmitters and thereby influences mood and behavior. Small-molecule MAO inhibitors (MAOIs) have been developed and are clinically used for treating depression and other neurological disorders. However, the involvement of MAO-A in antitumor immunity has not been reported. Here, we observed induction of the Maoa gene in tumor-infiltrating immune cells. Maoa knockout mice exhibited enhanced antitumor T cell immunity and suppressed tumor growth. MAOI treatment significantly suppressed tumor growth in preclinical mouse syngeneic and human xenograft tumor models in a T cell–dependent manner. Combining MAOI and anti–PD-1 treatments generated synergistic tumor suppression effects. Clinical data correlation studies associated intratumoral MAOA expression with T cell dysfunction and decreased patient survival in a broad range of cancers. We further demonstrated that MAO-A restrains antitumor T cell immunity through controlling intratumoral T cell autocrine serotonin signaling. Together, these data identify MAO-A as an immune checkpoint and support repurposing MAOI antidepressants for cancer immunotherapy.


Sign in / Sign up

Export Citation Format

Share Document